BioAtla, Inc.

Ladies and gentlemen, thank you for standing by. Your conference will begin momentarily. Thank you for your patience and please continue to stand by. Thank you. Thank you. Good day, and thank you for standing by. Welcome to the BioATLA first quarter 2022 financial results and business conference call. At this time, all participants are in a listen-only mode. After this week's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to Bruce Mackel, LifeSci Advisors. Please go ahead.

Thank you, operator, and good afternoon, everyone. With me today on the phone are Dr. Jay Short, chairman, CEO, and co-founder, Scott Smith, president, Philippe Martin, chief of clinical development and operations, Sherry Lydick, senior vice president, commercial strategy, and Richard Waldron, chief financial officer. Earlier today, BioAtla released financial results and a business update for the quarter ended March 31, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that statements made during this conference call that are not historical facts are forward-looking statements within the meaning of the federal securities laws. including but not limited to statements regarding our business plans and prospects, financial and operating performance and expectations, operating costs and expenses, products pipeline, clinical trial and regulatory timing, and associated resource requirements, our programs and potential partnerships, and the advancement of our CAB technology and product candidates. These forward-looking statements are based upon BioAtlas' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties as described in BioAtlas' annual report on Form 10-K, filed February 28, 2022, and subsequent filings with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on these statements. All forward-looking statements made during this conference call are based on management's assumptions and estimates as of today, May 4, 2022. BioATLA undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after today. except as required by law. With that, I'd like to turn the call over to Jay Short, chairman, CEO, and co-founder of BioAtla.

Jay? Thank you, Bruce. Thanks to everyone for joining us for our first quarter 2022 and first ever BioAtla earnings call. BioAtla is a clinical stage biotechnology company focused on transforming cancer therapy with the development of our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Our conditionally active biologics, or CAVs, target known and widely validated tumor antigens that have previously been difficult or impossible to target by exploiting characteristic pH differences between cancer cells and normal healthy cells. Since our IPO in December of 2020, The broad applicability of our CAB technology has allowed us to continue advancing the development of our innovative clinical and preclinical programs. We have five potentially registration-enabling ongoing Phase II trials for our two latest-stage CAB ADC product candidates, McBodimab-Vidotin or BA3011, and Ozuriptimab-Vidotin, or BA3021 across multiple solid tumor types for these first-in-class therapeutic candidates. BioAtla is also supporting a multicenter, investigated, initiated trial for both our lead assets in platinum-resistant ovarian cancer. Additionally, a phase one basket trial for our TABS CTLA-4 antibody, BA3071, has been initiated and is currently ongoing. Finally, BioAtla has several candidates in our IND enabling preclinical pipeline that include CAB, Bispecific, and Next Generation ADC antibodies targeting unmet medical needs in multiple types of solid tumors. We are pleased with our continued progress during the first quarter across our many clinical programs and believe we are well poised for another strong year of execution in 2022. Most importantly, we are excited to share the updates on our clinical ongoing clinical programs with you today. In particular, interim clinical data from our Phase II sarcoma study with our lead asset, BA3011. With that, I would now like to turn the call over to Philippe Martin, Chief of Clinical Development and Operations, to provide a top-line interim clinical data update from our Phase II sarcoma study. Philippe?